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Summary
Background Traditional genetic testing focusses on analysis of one or a few genes according to clinical features; this 
approach is changing as improved sequencing methods enable simultaneous analysis of several genes. Neonatal diabetes 
is the presenting feature of many discrete clinical phenotypes deﬁ ned by diﬀ erent genetic causes. Genetic subtype 
deﬁ nes treatment, with improved glycaemic control on sulfonylurea treatment for most patients with potassium channel 
mutations. We investigated the eﬀ ect of early, comprehensive testing of all known genetic causes of neonatal diabetes.
Methods In this large, international, cohort study, we studied patients with neonatal diabetes diagnosed with diabetes 
before 6 months of age who were referred from 79 countries. We identiﬁ ed mutations by comprehensive genetic 
testing including Sanger sequencing, 6q24 methylation analysis, and targeted next-generation sequencing of all known 
neonatal diabetes genes.
Findings Between January, 2000, and August, 2013, genetic testing was done in 1020 patients (571 boys, 449 girls). 
Mutations in the potassium channel genes were the most common cause (n=390) of neonatal diabetes, but were 
identiﬁ ed less frequently in consanguineous families (12% in consanguineous families vs 46% in non-consanguineous 
families; p<0·0001). Median duration of diabetes at the time of genetic testing decreased from more than 4 years 
before 2005 to less than 3 months after 2012. Earlier referral for genetic testing aﬀ ected the clinical phenotype. In 
patients with genetically diagnosed Wolcott-Rallison syndrome, 23 (88%) of 26 patients tested within 3 months from 
diagnosis had isolated diabetes, compared with three (17%) of 18 patients referred later (>4 years; p<0·0001), in 
whom skeletal and liver involvement was common. Similarly, for patients with genetically diagnosed transient 
neonatal diabetes, the diabetes had remitted in only ten (10%) of 101 patients tested early (<3 months) compared with 
60 (100%) of the 60 later referrals (p<0·0001).
Interpretation Patients are now referred for genetic testing closer to their presentation with neonatal diabetes. 
Comprehensive testing of all causes identiﬁ ed causal mutations in more than 80% of cases. The genetic result 
predicts the best diabetes treatment and development of related features. This model represents a new framework for 
clinical care with genetic diagnosis preceding development of clinical features and guiding clinical management.
Funding Wellcome Trust and Diabetes UK.
Copyright © De Franco et al. Open Access article distributed under the terms of CC BY.
Introduction
The traditional genetic testing approach is based on the 
selection of a gene or genes that are tested according to 
clinical phenotype. This approach places an emphasis on 
the recognition of clinical syndromes and results in mainly 
conﬁ rmatory genetic testing. The advent of next-generation 
sequencing has the potential to revolutionise the approach 
to diagnostic genetic testing, because both exome 
sequencing and custom gene-panel tests for speciﬁ c 
disorders analyse all genes known to cause a genetically 
heterogeneous disorder in one test (ﬁ gure 1).
Neonatal diabetes diagnosed before 6 months of age is 
a rare (incidence about one in 100 000 livebirths),1,2 
genetically heterogeneous disease, typically caused by 
mutations in one gene. By contrast, diabetes diagnosed 
after 6 months is most likely to be type 1 diabetes with 
an autoimmune cause.3,4 22 known genetic causes of 
neonatal diabetes exist (mutations in 21 genes and 
methylation abnormalities at the 6q24 locus) that 
identify diﬀ erent clinical subtypes of the disease. This 
includes isolated permanent neonatal diabetes, transient 
neonatal diabetes, and complex syndromes in which 
neonatal diabetes is often the presenting feature (eg, 
Wolcott-Rallison syndrome). Traditional genetic testing 
for neonatal diabetes requires accurate clinical 
information about the patient’s phenotype to allow 
selection of a small number of genes to test. Because 
neonatal diabetes is generally the presenting feature of 
the disease, this approach is restricted by the clinical 
information available at the time of referral and relies on 
timely clinical updates on the subsequent development 
of additional features from the referring clinicians.
The most common causes of neonatal diabetes are 
mutations in the potassium channel subunit genes 
ABCC8 and KCNJ11.5–7 Patients with neonatal diabetes 
caused by a potassium channel gene mutation are 
sensitive to sulfonylurea treatment and therefore their 
clinical management can be improved by replacing 
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insulin with oral agents.8–11 This situation highlights the 
importance of early genetic diagnosis in neonatal 
diabetes, and international guidelines suggest immediate 
referral for genetic testing as soon as a clinical diagnosis 
of neonatal diabetes is made.12
Three targeted next-generation sequencing assays 
have been developed for genetic testing of monogenic 
diabetes,13–15 including our panel that includes all the 
known neonatal diabetes genes.14 A methylation assay is 
needed to detect 6q24 abnormalities. We used the 
targeted next-generation sequencing assay to test all the 
genetically undiagnosed patients in a large, international 
cohort of 1020 patients with diabetes with the objective 
of assessing the eﬀ ect of early, comprehensive genetic 
testing in this disease.
Methods
Patients
Between January, 2000, and August, 2013, genetic testing 
was done in 1020 patients (571 boys, 449 girls) diagnosed 
with diabetes before 6 months of age who were referred 
to the Exeter Molecular Genetics laboratory from 
79 countries. We excluded 85 patients for whom there 
was insuﬃ  cient DNA available for comprehensive 
testing (appendix). Clinical information was provided by 
the referring clinicians from clinical notes via completion 
of a neonatal diabetes request form. Genetic testing for 
neonatal diabetes was oﬀ ered free of charge. The study 
was done in accordance with the Declaration of Helsinki 
principles with informed parental consent given on 
behalf of children.
The median age at diagnosis of diabetes was 6 weeks 
(IQR Q1–Q3 1–12), and the median birthweight was 2460 g 
(median standard deviation score [SDS] –1·7 [–2·6 to 0·8], 
median centile 4·7 [0·5–22·8]). We deﬁ ned patients born 
to consanguineous parents as those whose parents were 
ﬁ rst or second cousins (n=215), or those from countries 
with a high prevalence (>20%) of consanguineous unions16 
(appendix) in whom genome-wide SNP typing showed 
genomic homozygosity of 1·56% or higher,17 as previously 
described18 (n=15; appendix). We used the Chi-square test 
to assess the diﬀ erences between the consanguineous and 
non-consanguineous groups.
Molecular genetic testing
All patients were tested until a causative mutation was 
identiﬁ ed by Sanger sequencing or targeted next-
generation sequencing14 for all 21 known neonatal 
diabetes genes or by methylation analysis for chromosome 
6q24 abnormalities. The appendix shows the current 
testing pipeline.
Initial analysis consisted of rapid (<2 weeks) Sanger 
sequencing of KCNJ11, ABCC8, and INS19 with testing 
for chromosome 6q24 abnormalities by methylation 
analysis20 in patients with a clinical diagnosis of transient 
neonatal diabetes, or those patients younger than 
6 months at the time of testing. Since 2012, this initial 
testing was followed by comprehensive testing of all 
other genes by the targeted next-generation sequencing 
assay. Before 2012, additional genes were sequenced by 
Sanger sequencing according to clinical features or as 
part of a cohort analysis when a new gene was discovered 
and the phenotype needed to be deﬁ ned.
In all patients for whom a genetic diagnosis had not 
been identiﬁ ed by this initial testing, we used a custom 
targeted next-generation sequencing panel14 to sequence 
all known neonatal diabetes genes (appendix). This 
assay used the Agilent SureSelect in solution capture 
system. We adjusted bait density and replication from 
Agilent (version 1) exome capture data to achieve more 
even coverage over the targeted genes. A minimum 
coverage of 30 reads per base for the coding region 
±50 bp was achieved for 98·5% of bases. Partial or whole 
gene deletions or duplications were identiﬁ ed by relative 
read depth coverage as previously described.14 The 
mutations identiﬁ ed by targeted next-generation 
sequencing were conﬁ rmed by Sanger sequencing or 
multiplex ligation-dependent probe ampliﬁ cation.
Figure 1: The paradigm shift of genetic testing
Schematic representation of the steps involved in genetic testing before and after the introduction of next-generation sequencing. The red boxes indicate the role of 
genetic testing.
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We used the bioinformatic method ALAMUT 
(Interactive Biosoftware, Rouen, France) to predict the 
eﬀ ect of novel variants. We used microsatellite analysis 
of parent and proband trios using the PowerPlex 16 kit 
(Promega, Southampton, UK) to conﬁ rm biological 
associations in probands with apparently de-novo 
mutations. 253 (25%) of the 1020 patients had been 
included in previous publications (appendix).
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the manuscript. The corresponding author 
had full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We identiﬁ ed the genetic cause of neonatal diabetes in 
840 (82%) of 1020 patients. The proportion of patients for 
whom a genetic diagnosis could not be identiﬁ ed was 
similar in patients born to unrelated parents and related 
parents (18% in infants with non-consanguineous parents 
vs 15% with consanguineous parents; p=0·27; df=1). 
These data suggest that both dominant and recessive 
causes of neonatal diabetes are still undiscovered (ﬁ gure 2 
and appendix).
Parental consanguinity made a striking diﬀ erence to the 
mode of inheritance of neonatal diabetes (ﬁ gure 2). The 
major diﬀ erence was that, as expected, recessive causes 
were common (158 [81%] of 195 patients) in the oﬀ spring 
of consanguineous parents but unusual (81 [13%] of 
645 patients) when the parents were not consanguineous 
(p<0·0001; df=1). Dominant heterozygous mutations were 
more common (457 [71%] of 645 patients) in the oﬀ spring 
Figure 2: Diﬀ erent genetic causes of neonatal diabetes in patients born to 
non-consanguineous and consanguineous parents
Comparison of genetic causes of neonatal diabetes in non-consanguineous 
(n=790) and consanguineous groups (n=230). Consanguinity is deﬁ ned by 
parents being second cousins or more closely related or by the presence of 1·56% 
or higher total homozygosity.17 Genes mutated in fewer than 2·5% of patients in 
both cohorts were grouped in the other category (appendix).
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Figure 3: A genetic diagnosis guides clinical management
Schematic representation of genetic causes of neonatal diabetes and the 
implications of this genetic diagnosis. N indicates the number of patients 
identiﬁ ed with mutations in each of the genes in the 1020 neonatal diabetes 
patient cohort. Solid arrows indicate implications for most mutations in the 
genes. Dashed arrows indicate the implications for speciﬁ c mutations.
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of non-consanguineous parents and most of them were 
spontaneous (216 [68%] of 320 patients when both parents 
were available for testing).
The major genetic cause diﬀ ered depending on 
whether the parents were related. Mutations in KCNJ115 
and ABCC86,7 accounted for 46% of cases in the 
non-consanguineous cohort, but only 12% in the 
consanguineous group (p<0·0001; df=1). This is an 
important diagnosis because glycaemic control can be 
substantially improved for most of these patients by 
transferring from insulin injections to high-dose 
sulfonylurea tablets.9,11 In patients born to consanguineous 
parents, the most common cause (56/230 [24%]) of 
neonatal diabetes was a homozygous mutation in the 
EIF2AK3 gene causing Wolcott-Rallison syndrome.21
Mutations in the INS gene were present at a similar 
proportion in the two groups (11% of patients with 
non-consanguineous parents vs 10% of infants with 
consanguineous parents; p=0·89; df=1), but the 
mechanism underlying the disease is fundamentally 
diﬀ erent. In the non-consanguineous group, most INS 
gene mutations were heterozygous (77 [90%] of 
86 patients) and aﬀ ected the structure of the preproinsulin 
protein.22 Data from mouse models and in-vitro studies 
suggest that these mutations result in altered protein 
folding causing severe endoplasmic reticulum stress 
and ultimately β-cell destruction. Of patients born to 
consanguineous parents, INS mutations were mainly 
(18 [75%] of 24 patients) homozygous loss-of-function 
changes that impaired the synthesis of insulin.23 
The diﬀ erent genetic causes of neonatal diabetes 
identiﬁ ed so far have a range of both pancreatic and 
extra-pancreatic phenotypes (ﬁ gure 3). The speciﬁ c 
subtypes have been described in detail elsewhere and are 
summarised in the appendix.
The pancreatic phenotypes include transient neonatal 
diabetes (6q24, ABCC8, KCNJ11, INS, HNF1B, SLC2A2, 
ZFP57 subtypes), in which the diabetes resolves 
(n=219), permanent diabetes responding to sulfonylurea 
treatment (KCNJ11 and ABCC8, n=299), permanent 
insulin-treated diabetes (INS, GCK, EIF2AK3, FOXP3, 
GLIS3, NEUROD1, NEUROG3, NKX2-2, MNX1, 
IER3IP1, RFX6, and some cases with GATA6, GATA4 
and PDX1 mutations, n=265), and developmental 
disorders of the exocrine pancreas (GATA6, PTF1A, 
PDX1 and GATA4) requiring pancreatic enzyme 
replacement in addition to insulin treatment (n=50). 
Diabetes caused by SLC19A2 gene mutations can 
sometimes be successfully treated with thiamine (n=7). 
Therefore, the identiﬁ cation of the genetic cause 
deﬁ nes the treatment requirements for the endocrine 
and exocrine pancreatic function.
Speciﬁ c extra-pancreatic features are associated with 
diﬀ erent genetic subtypes of neonatal diabetes, with 
neurological features being the most common (n=184). 
Mutations in nine genes (ABCC8 [22% of cases], KCNJ11 
[29% of cases], EIF2AK3, SLC19A2, IER3IP1, PTF1A, 
NEUROD1, MNX1, and NKX2-2) cause neonatal diabetes 
with neurological abnormalities. These additional 
features generally become evident in infancy, after 
diagnosis of neonatal diabetes; therefore, early genetic 
diagnosis in these patients predicts future development 
of neurological complications.
Figure 4: Genetic diagnosis precedes development of additional clinical features deﬁ ning the neonatal 
diabetes subtype
(A) Eﬀ ect of early genetic diagnosis in transient neonatal diabetes caused by 6q24 methylation defects or
potassium channel gene mutations. Bar chart representing clinical features at the time of genetic testing for
neonatal diabetes. Orange=diabetes, purple=diabetes remitted. (B) The eﬀ ect of age at genetic
testing on whether patients have non-diabetes features of Wolcott-Rallison Syndrome at the time of referral for
genetic testing. Bar chart representing clinical features at the time of genetic testing for neonatal diabetes.
Orange=diabetes only, light blue=diabetes and either skeletal abnormalities or liver dysfunction, dark 
blue=diabetes, skeletal abnormalities, and liver dysfunction. (C) The eﬀ ect of age at genetic testing on whether
patients with a KCNJ11 p.Val59Met mutation have neurological features at the time of referral for genetic testing.
Bar chart representing clinical features at the time of genetic testing for neonatal diabetes. Orange=diabetes only,
green=diabetes and neurological features.
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We investigated the diﬀ erences in referral rate and 
age at referral in the referral period. The median time 
from the diagnosis of diabetes to referral for genetic 
testing showed a marked decrease from more than 
4 years (240 weeks, IQR 218–4099) in 2004, to less than 
3 months (10 weeks, IQR 3–23) since 2012 (appendix). 
The number of referrals per year was steady during the 
past 10 years at 80–100 per year (appendix) although 
there has been a shift from prevalent cases to incident 
cases as shown in the median duration of diabetes 
at referral.
We investigated the eﬀ ect of decreased time from 
diagnosis to referral for genetic testing to see whether 
this resulted in patients having a genetic diagnosis before 
they developed typical clinical features of their genetic 
cause. We assessed the eﬀ ect of early genetic testing in 
the 210 patients with a genetic diagnosis of transient 
neonatal diabetes caused by 6q24 methylation defects or 
potassium channel gene mutations (ﬁ gure 4A). The 
likelihood that the patient’s diabetes had remitted before 
referral was dependent on the time from diagnosis to 
genetic testing; only 10 (10%) of 101 patients tested early 
(<3 months from diagnosis) had remitted by the time of 
genetic testing but 60 (100%) of 60 late referrals 
(>48 months after diagnosis) had entered remission 
when genetic testing was done (p<0·0001, df=1).
We identiﬁ ed recessive mutations in EIF2AK3, which 
conﬁ rm a genetic diagnosis of Wolcott-Rallison syndrome, 
in 76 patients. Wolcott-Rallison syndrome is caused by 
biallelic mutations in EIF2AK3, a gene known to be 
important for regulation of endoplasmic reticulum 
stress.21 A clinical diagnosis of Wolcott-Rallison syndrome 
requires the presence of insulin-dependent diabetes and 
skeletal dysplasia or liver dysfunction.33 Although most of 
these patients are diagnosed with diabetes in the ﬁ rst 
6 months of life, skeletal dysplasia is not evident until the 
infant is 1 or 2 years of age and liver dysfunction generally 
manifests during intercurrent illness as recurrent 
episodes of acute liver failure which can present at any 
time after the neonatal diabetes. The non-diabetes 
features were present only in 3 (12%) of 26 patients with 
early referral (<3 months from diagnosis of diabetes) but 
were found in most patients (15 [83%] of 18) with late 
referral (>48 months from diagnosis of diabetes; 
p<0·0001, df=1; ﬁ gure 4B).
Speciﬁ c mutations in KCNJ11 and ABCC8 cause a 
syndromic form of neonatal diabetes characterised by 
severe development delay and neurological features 
(DEND [Developmental delay, Epilepsy and Neonatal 
Diabetes] and iDEND syndrome).5,7 The most common of 
these mutations is KCNJ11 p.Val59Met which was 
detected in 26 patients in our cohort. Among these 
patients, neurological features were not present in any of 
those with early referral (0 of 7 referred <3 months from 
diagnosis) but were found in 14 (100%) of 14 patients 
with late referral (>48 months from diagnosis of diabetes, 
p<0·0001, df=1; ﬁ gure 4C).
Discussion
Patients with neonatal diabetes are referred for genetic 
testing close to their presentation with hyperglycaemia, 
often before other features have developed or are 
recognised. Comprehensive testing (including next-
generation sequencing) of the known genetic causes of 
neonatal diabetes identiﬁ ed causal mutations in more 
than 80% of cases. An early genetic diagnosis predicts the 
best available diabetes treatment and allows anticipation 
of the development of related features. Therefore, 
neonatal diabetes is a good example of how early 
comprehensive genetic testing including next-generation 
sequencing can improve clinical management of a 
genetically heterogeneous disease (panel). This approach 
will probably have implications for many other genetically 
heterogeneous disorders such as hereditary hearing 
loss,24 congenital muscular dystrophy,25 and inherited 
retinal diseases.26 Gene panels for early genetic diagnosis 
of these disorders have already been developed and can 
be used to identify subsets of patients who are eligible for 
gene therapy.26 The paradigm shift in genetic testing has 
probably happened earlier for neonatal diabetes as a 
consequence of the availability of a free, comprehensive 
test and, importantly, because of the possibility of 
treatment change for almost 40% of patients.
Neonatal diabetes is a clinically and genetically 
heterogeneous disease, with 22 known genetic causes. 
Diﬀ erent genetic defects deﬁ ne the clinical subtypes of 
neonatal diabetes with important implications for clinical 
management and treatment (ﬁ gure 3, appendix pp 9–10). 
About 40% of patients in our cohort have a mutation in a 
potassium channel subunit gene (ABCC8 and KCNJ11) 
and most achieve improved glycaemic control upon 
transfer from insulin therapy to high dose sulfonylureas.9,11
210 (20%) of 1020 patients in our cohort had a genetic 
diagnosis of transient neonatal diabetes caused by 
methylation abnormalities resulting in overexpression 
of the paternally inherited allele of genes at the 6q24 
locus27–29 or mutations in ABCC8 or KCNJ11.30 Patients 
with transient neonatal diabetes caused by a potassium 
channel mutation tend to be diagnosed and remit later 
than patients with 6q24 methylation abnormalities 
(median age at diagnosis 4 weeks in patients with 
potassium channel mutation vs 0 weeks in patients 
with 6q24 methylation abnormalities, median age at 
remission 35 weeks vs 13 weeks).7,31,32 With the decrease 
in the age at referral in our cohort, 105 (50%) of 
210 transient neonatal diabetes patients were referred 
before diabetes remission. Of the 101 (48%) of 
210 patients referred less than 3 months from diagnosis, 
90% (n=91) received a genetic diagnosis of transient 
neonatal diabetes before diabetes remission (ﬁ gure 4A). 
These data suggest a radical change in the role of genetic 
testing in neonatal diabetes, in which for most patients 
the genetic test predicts whether the diabetes will be 
transient or permanent, in addition to guiding treatment 
decisions (ﬁ gure 3).
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Neonatal diabetes is a clinical feature of 16 syndromes 
caused by mutations in 17 genes and in most of them it 
is the presenting feature. Our ﬁ ndings show that, 
during the past 10 years, the median time from clinical 
diagnosis to referral for genetic testing has fallen from 
more than 4 years to less than 3 months (appendix p 4). 
As a result, most patients now have genetic testing 
before development of the additional clinical features 
that characterise the syndrome. We investigated the 
eﬀ ect of early genetic testing in the most common of 
these syndromes, Wolcott-Rallison syndrome. 46 (61%) 
of 76 patients in our cohort received a genetic diagnosis 
of Wolcott-Rallison syndrome before development of 
either skeletal dysplasia or liver failure. This proportion 
was even higher (89% [n=23]) for patients with early 
referral (<3 months from diagnosis; ﬁ gure 4B). An early 
diagnosis of Wolcott-Rallison Syndrome is important to 
ensure rapid management of episodes of acute liver 
failure, which is a life threatening complication in 
these patients.
Activating mutations in ABCC8 and KCNJ11 are 
associated with a variable spectrum of phenotypes 
according to genotype;34 milder mutations cause transient 
neonatal diabetes, whereas mutations that severely aﬀ ect 
the potassium channels’ ability to respond to ATP 
concentrations cause permanent neonatal diabetes 
associated with neurological features (ie, intermediate 
DEND syndrome and DEND syndrome;5,7,30 ﬁ gure 3, 
appendix). The most common of these mutations is the 
KCNJ11 p.Val59Met, which was identiﬁ ed in 26 patients in 
our cohort. Of these patients, 100% of those referred for 
genetic testing less than 12 months after clinical diagnosis 
of diabetes had genetic testing before development of 
additional neurological features (ﬁ gure 4C). This ﬁ nding 
is extremely important because ﬁ ndings of previous 
studies have shown that high dose sulfonylurea therapy 
can improve neurological symptoms in patients with 
iDEND and DEND.35,36 In these cases, an early genetic 
diagnosis provides clinicians with valuable information 
for the patients’ clinical management, suggesting the 
possibility of treatment change and awareness of the 
development of neurological features.
The awareness of future development of additional 
clinical features as a consequence of the genetic diagnosis 
has important implications for patients with other 
neonatal diabetes-associated syndromes, such as IPEX 
syndrome, a severe multi-organ autoimmune disease 
caused by a mutation in FOXP3.37 Onset is usually within 
the ﬁ rst months of life, with one of the three cardinal 
features: severe enteropathy, eczema, or diabetes. An 
early genetic diagnosis of IPEX syndrome is crucial for 
clinical management and treatment because early 
allogenic haematopoietic stem cell transplant results in 
the best outcome.38
In conclusion, our study describes the transformation 
that can occur in clinical practice once genetic testing 
becomes the initial investigation. Traditionally, genetic 
testing was used to conﬁ rm a clinical diagnosis based on 
disease course or a cluster of clinical features. Now, early 
comprehensive genetic testing gives a diagnosis before 
the development of speciﬁ c features (ﬁ gure 1). The future 
of care in neonatal diabetes will increasingly rely on the 
results of genetic testing with the genetic diagnosis, not 
only informing a clinician of the likely course and best 
treatment for the diabetes, but also predicting 
development of additional clinical features. This model 
represents a new framework in which genetic testing 
deﬁ nes, rather than just conﬁ rms, the clinical diagnosis.
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Panel: Research in context
Systematic review
Between Jan 1, 2000, and Jan 1, 2014, we searched PubMed with the MeSH search terms 
“Neonatal Diabetes” OR “PNDM” OR “TNDM” AND “genetic testing” OR “sequencing” OR 
“mutation” for articles published before Jan 1, 2014, describing genetic testing in neonatal 
diabetes. None of the articles identiﬁ ed by this search assessed the results and eﬀ ect of 
comprehensive genetic testing in patients with neonatal diabetes. We found two studies 
describing the development of targeted next generation sequencing approaches for genetic 
testing in neonatal diabetes,13,15 but they only described their use in small validation studies. 
The large study of 174 neonatal diabetes patients by Busiah and colleagues32 reported the 
analysis of the four commonest of the known genetic causes. Several studies have described 
the improvement in glycaemic control in patients with a KCNJ11 or ABCC8 mutation after 
transferral from insulin to sulfonylurea therapy.7–10 We found no data to suggest whether the 
progress in genetic testing has resulted in reduced time from diagnosis of diabetes to 
referral for genetic analysis during the past decade or the eﬀ ect of early genetic diagnosis on 
the clinical management of patients. Therefore, we undertook comprehensive testing in a 
large cohort of patients with neonatal diabetes to assess how an early genetic diagnosis 
might aﬀ ect clinical care.
Interpretation
Our ﬁ ndings provide an accurate estimation of the molecular contribution and clinical 
features of the known genetic causes of neonatal diabetes. Patients are referred for 
genetic testing soon after diagnosis, often when they only have isolated diabetes. Our 
results show that early comprehensive genetic testing allows identiﬁ cation of the 
underlying genetic defect in about 82% of patients. The genetic diagnosis will inform 
clinicians on the probable course and best management of the patient’s diabetes and the 
likely future development of additional clinical features. This represents a new framework 
for clinical care in neonatal diabetes, with genetic diagnosis often preceding development 
of clinical features and guiding clinical management.
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